- Data from clinical trials showed the Chinese military vaccine had a "good safety profile" and potential to prevent disease.
Hong Kong-listed CanSino Biologics said in a filing to the stock exchange that data from clinical trials showed the Chinese military vaccine had a "good safety profile" and potential to prevent disease caused by the novel coronavirus.
CanSino said that China's Central Military Commission approved the use of the vaccine on June 25, for one year.
The vaccine was jointly developed by CanSino and the Beijing Institute of Biotechnology, part of the Academy of Military Medical Sciences.
CanSino added that it cannot guarantee the vaccine - which had its phase one and two clinical trials done in China - will ultimately be commercialised.
No comments :
Post a Comment